OCT4: A novel biomarker for dysgerminoma of the ovary

American Journal of Surgical Pathology

Volumn 28, Issue 10, 2004, Pages 1341-1346

  Cheng, Liang ^a,d   Thomas, Antoinette ^a   Roth, Lawrence M ^a   Zheng, Wenxin ^c   Michael, Helen ^a   Karim, Fadi W Abdul ^b  

^a INDIANA UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adolescent; Biomarker; Differential diagnosis; Dysgerminoma; Germ cell tumors; Gonadoblastoma; Histogenesis; Neoplasia; OCT3 4; Ovary; POU5F1

Indexed keywords

FORMALDEHYDE; OCTAMER TRANSCRIPTION FACTOR 4; PARAFFIN; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANDROBLASTOMA; ARTICLE; BRENNER TUMOR; CARCINOID; CLEAR CELL CARCINOMA; DYSGERMINOMA; EMBRYO DEVELOPMENT; ENDOMETRIOID CARCINOMA; FEMALE; FIBROMA; GONADOBLASTOMA; GRANULOSA CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; LYMPHOMA; METASTASIS; PLURIPOTENT STEM CELL; SMALL CELL CARCINOMA; TERATOMA; THECOMA; YOLK SAC TUMOR;

ADENOCARCINOMA, CLEAR CELL; ADOLESCENT; ADULT; CELL NUCLEUS; CHILD; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; DYSGERMINOMA; FEMALE; GONADOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NECROSIS; OCTAMER TRANSCRIPTION FACTOR-3; OVARIAN NEOPLASMS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 5044233906     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pas.0000135528.03942.1f     Document Type: Article

References (35)

1. Bjorkholm E, Lundell M, Gyftodimos A, et al. Dysgerminoma: the Radiumhemmet series 1927-1984. Cancer. 1990;65:38-44.
2. Burke AP, Mostofi FK, Placental alkaline phosphatase immunohistochemistry of intratubular malignant germ cells and associated testicular germ cell tumors. Hum Pathol. 1988;19:663-670.
3. Cheng L. Establishing germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Mod Pathol. 2004;17:605A.
4. Cheng L, Leibovich BC, Bergstralh EJ, et al. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression? Cancer. 1999;85:2455-2459.
5. Cheng L, Lloyd RV, Weaver AL, et al. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res. 2000;6:1896-1899.
6. Cheng L, Nagabhushan M, Pretlow TP, et al. E-cadherin expression in primary and metastatic prostate cancer. Am J Pathol. 1996;148:1375-1380.
7. Cheng L, Pan C, Zhang JT, et al. Loss of 14-3-3σ in prostate cancer and its precursors. Clin Cancer Res. 2004;10:3064-3068.
8. Cheng L, Pisansky TM, Sebo TJ, et al. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res. 1999;5:2820-2823.
9. Cheng L, Sebo TJ, Cheville JC, et al. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer. 1999;85:1293-1299.
10. Culine S, Lhomme C, Kattan J, et al. Cisplatin-based chemotherapy in dysgerminoma of the ovary: thirteen-year experience at the Institut Gustave Roussy. Gynecol Oncol. 1995;58:344-348.
11. De Palo G, Pilotti S, Kenda R, et al. Natural history of dysgerminoma. Am J Obstet Gynecol. 1982;143:799-807.
12. Gallion HH, van Nagell JR Jr, Donaldson ES, et al. Ovarian dysgerminoma: report of seven cases and review of the literature. Am J Obstet Gynecol. 1988;158:591-595.
13. Gordon A, Lipton D, Woodruff JD. Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry. Obstet Gynecol. 1981;58:497-504.
14. Greene FL, Page DL, Flemming ID, et al. American Joint Committee on Cancer Staging Manual, 6th ed. New York: Springer-Verlag, 2002.
15. Guillaudeux T, Mattei MG, Depetris D, et al. In situ hybridization localizes the human OTF3 to chromosome 6p21.3→p22 and OTF3L to 12p13. Cytogenet Cell Genet. 1993;63:212-214.
16. Hansis C, Grifo JA, Krey LC. Oct-4 expression in inner cell mass and trophectoderm of human blastocysts. Mol Hum Reprod. 2000;6:999-1004.
17. Hansis C, Tang YX, Grifo JA, et al. Analysis of Oct-4 expression and ploidy in individual human blastomeres. Mol Hum Reprod. 2001;7:155-161.
18. Jones TD, Ulbright TM, Eble JN, et al. OCT4 is a sensitive and specific marker for testicular seminoma and embryonal carcinoma. Am J Surg Pathol. 2004;28:935-940.
19. Koonings PP, Campbell K, Mishell DRJ, et al. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74:921-926.
20. Lifschitz-Mercer B, Walt H, Kushnir I, et al. Differentiation potential of ovarian dysgerminoma: an immunohistochemical study of 15 cases. Hum Pathol. 1995;26:62-66.
21. Looijenga LH, Stoop H, de Leeuw HP, et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 2003;63:2244-2250.
22. Miettinen M, Wahlstrom T, Virtanen I, et al. Cellular differentiation in ovarian sex-cord-stromal and germ-cell tumors studied with antibodies to intermediate-filament proteins. Am J Surg Pathol. 1985;9:640-651.
23. Okamoto K, Okazawa H, Okuda A, et al. A novel octamer binding transcription factor is differentially expressed in mouse embryonic cells. Cell. 1990;60:461-472.
24. Parkash V, Carcangiu ML. Transformation of ovarian dysgerminoma to yolk sac tumor: evidence for a histogenetic continuum. Mod Pathol. 1995;8:881-887.
25. Pesce M, Wang X, Wolgemuth DJ, et al. Differential expression of the Oct-4 transcription factor during mouse germ cell differentiation. Mech Dev. 1998;71:89-98.
26. Rosner MH, Vigano MA, Ozato K, et al. A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature. 1990;345:686-692.
27. Scholer HR, Dressler GR, Balling R, et al. Oct-4: a germline-specific transcription factor mapping to the mouse t-complex. EMBO J. 1990;9:2185-2195.
28. Scully RE, Young RH, Clement PB. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Washington, DC: Armed Forces Institute of Pathology, 1998.
29. Teilum G. Classification of endodermal sinus tumor (mesoblastoma vitellinum) and so-called 'embryonal carcinoma' of the ovary. Acta Pathol Microbiol Scand. 1965;64:407-429.
30. Van Niekerk CC, Ramaekers FC, Hanselaar AG, et al. Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am J Pathol. 1993;142:157-177.
31. Williams SD. Ovarian germ cell tumors: an update. Semin Oncol. 1998;25:407-413.
32. Williams SD, Blessing JA, Hatch KD, et al. Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. J Clin Oncol. 1991;9:1950-1955.
33. Witschi E. Migration of the germ cells of human embryos from the yolk sac to the primitive gonadal folds. Contrib Emryol. 1948;32:69-80.
34. Zaghloul MS, Khattab TY. Dysgerminoma of the ovary: good prognosis even in advanced stages. Int J Radiat Oncol Biol Phys. 1992;24:161-165.
35. Zeng G, Hu Z, Kinch MS, et al. High-level expression of EphA2 receptor tyrosine kinase in prostatic intraepithelial neoplasia. Am J Pathol. 2003;163:2271-2276.